Ionis Pharmaceuticals Stock (NASDAQ:IONS)
Previous Close
$38.76
52W Range
$35.95 - $54.44
50D Avg
$41.60
200D Avg
$43.87
Market Cap
$6.06B
Avg Vol (3M)
$1.55M
Beta
0.38
Div Yield
-
IONS Company Profile
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of TTR amyloidosis; Olezarsen for patients with severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Tofersen to inhibit the production of superoxide dismutase 1. In addition, the company develops medicines for metabolic diseases, infectious diseases, renal diseases, ophthalmic diseases, and cancer. It has a strategic collaboration with Biogen Inc.; and collaboration and license agreement with AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis AG, Roche, Janssen Biotech, Inc., and Flamingo Therapeutics, Inc. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
IONS Performance
Revenue Breakdown
Revenue Breakdown by Product/Service
Product/Service | Dec 23 | Dec 22 | Dec 21 |
---|---|---|---|
SPINRAZA Royalties | $240.38M | - | - |
Licensing and Other Royalties | $33.30M | $30.99M | $19.12M |
Other Commercial | $68.21M | - | - |
Product | $34.91M | $30.05M | - |
Research and Development Revenue | $479.06M | $284.01M | - |
Commercial | $308.59M | $303.36M | $342.39M |
Collaborative Agreement Revenue | $352.66M | $207.22M | - |
Spinraza Royalties | - | $242.31M | $267.78M |
Eplontersen Joint Development Revenue | - | $76.79M | - |
Research and Development Revenue Under Collaborative Agreements | - | - | $468.06M |
TEGSEDI and WAYLIVRA | - | - | $55.50M |
Peer Comparison
Ticker | Company |
---|---|
INCY | Incyte Corporation |
ARWR | Arrowhead Pharmaceuticals, Inc. |
AKRO | Akero Therapeutics, Inc. |
PTCT | PTC Therapeutics, Inc. |
IOVA | Iovance Biotherapeutics, Inc. |
APLS | Apellis Pharmaceuticals, Inc. |
EXEL | Exelixis, Inc. |
HALO | Halozyme Therapeutics, Inc. |
SRPT | Sarepta Therapeutics, Inc. |
BMRN | BioMarin Pharmaceutical Inc. |
ALNY | Alnylam Pharmaceuticals, Inc. |
TERN | Terns Pharmaceuticals, Inc. |
VKTX | Viking Therapeutics, Inc. |
KRYS | Krystal Biotech, Inc. |
MDGL | Madrigal Pharmaceuticals, Inc. |